Table 3.
Treatment of mixed/psychotic mania across practice guidelines
| Guidelines | First-line treatment | Next-step intervention | Later intervention |
|---|---|---|---|
| KMAP-BP 201412 | Mixed mania: Val or Li + AAP | Li or Val + AAP, Li or Val + | Two AAPs + Li + Val, Li + |
| Psychotic mania: Val or Li + AAP, AAP | two AAPs, Val + Li + AAP | Val + other AAP | |
| BAP 200913 | Same as for euphoric mania; AAP in psychotic mania | Same as for euphoric mania | Same as for euphoric mania |
| CANMAT 201314 | Not mentioned | ||
| NICE 201415 | Same as for euphoric mania | Same as for euphoric mania | Same as for euphoric mania |
| WFSBP 200916 | Val, AAP (OLZ, ZIP, ARP) | RIS, CBZ |
Abbreviations: KMAP-BP 2014, Korean Medication Algorithm Project for Bipolar Disorder 2014; BAP 2009, The British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder 2009; CANMAT 2013, Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Patients with Bipolar Disorder 2013; NICE 2014, National Institute for Health and Clinical Excellence Clinical Guideline for Bipolar Disorder 2014; WFSBP 2009, World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Bipolar Disorder 2009 (treatment of acute mania); Val, various kinds of valproic acids; Li, lithium; AAP, atypical antipsychotic; OLZ, olanzapine; ZIP, ziprasidone; ARP, aripiprazole; RIS, risperidone; CBZ, carbamazepine.